Cargando…
The potential impact of Covid-19 on the capacity of routine laboratory tests to detect heparin-induced thrombocytopenia
In Covid-19, anticoagulation with heparin is often administered to prevent or treat thromboembolic events. Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin treatment, caused by heparin-dependent, platelet activating anti-platelet factor 4 (PF4)/heparin antibodies. Diagnosis...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510722/ https://www.ncbi.nlm.nih.gov/pubmed/36163073 http://dx.doi.org/10.1186/s12959-022-00411-0 |
_version_ | 1784797501812899840 |
---|---|
author | Draxler, Dominik F. Brodard, Justine Zante, Björn Jakob, Stephan M. Wiegand, Jan Kremer Hovinga, Johanna A. Angelillo-Scherrer, Anne Rovo, Alicia |
author_facet | Draxler, Dominik F. Brodard, Justine Zante, Björn Jakob, Stephan M. Wiegand, Jan Kremer Hovinga, Johanna A. Angelillo-Scherrer, Anne Rovo, Alicia |
author_sort | Draxler, Dominik F. |
collection | PubMed |
description | In Covid-19, anticoagulation with heparin is often administered to prevent or treat thromboembolic events. Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin treatment, caused by heparin-dependent, platelet activating anti-platelet factor 4 (PF4)/heparin antibodies. Diagnosis of HIT is based on the combination of clinical parameters, allowing to determine the pretest probability, and laboratory testing for anti-PF4/heparin antibodies and confirmatory functional assays, such as the heparin-induced platelet activation (HIPA) test. We report the case of a patient with severe Covid-19 pneumonia requiring ECMO treatment, who developed recurrent clotting of the ECMO filter and a drop in platelet count under heparin treatment. He was therefore suspected to have HIT and the anticoagulation was switched to argatroban. Despite high clinical probability and high titres of anti-PF4/heparin antibodies, the functional HIPA test was negative. Nevertheless, argatroban was continued rather than to reinstate anticoagulation with heparin. Reevaluation 7 days later then demonstrated a strongly positive functional HIPA test and confirmed the diagnosis of HIT. Under anticoagulation with argatroban the patient gradually improved and was finally weaned off the ECMO. In conclusion, this case highlights the critical importance of clinical judgement, exploiting the 4 T score, given that Covid-19 patients may present a different pattern of routine laboratory test results in HIT diagnostics. The possibility of a false negative HIPA test has to be considered, particularly in early phases of presentation. In cases of a discrepancy with high clinical probability of HIT and/or high titre anti-PF4/heparin antibodies despite a negative HIPA test, a reevaluation within 3 to 5 days after the initial test should be considered in order to avoid precipitant reestablishment of unfractionated heparin, with potentially fatal consequences. |
format | Online Article Text |
id | pubmed-9510722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95107222022-09-26 The potential impact of Covid-19 on the capacity of routine laboratory tests to detect heparin-induced thrombocytopenia Draxler, Dominik F. Brodard, Justine Zante, Björn Jakob, Stephan M. Wiegand, Jan Kremer Hovinga, Johanna A. Angelillo-Scherrer, Anne Rovo, Alicia Thromb J Case Report In Covid-19, anticoagulation with heparin is often administered to prevent or treat thromboembolic events. Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin treatment, caused by heparin-dependent, platelet activating anti-platelet factor 4 (PF4)/heparin antibodies. Diagnosis of HIT is based on the combination of clinical parameters, allowing to determine the pretest probability, and laboratory testing for anti-PF4/heparin antibodies and confirmatory functional assays, such as the heparin-induced platelet activation (HIPA) test. We report the case of a patient with severe Covid-19 pneumonia requiring ECMO treatment, who developed recurrent clotting of the ECMO filter and a drop in platelet count under heparin treatment. He was therefore suspected to have HIT and the anticoagulation was switched to argatroban. Despite high clinical probability and high titres of anti-PF4/heparin antibodies, the functional HIPA test was negative. Nevertheless, argatroban was continued rather than to reinstate anticoagulation with heparin. Reevaluation 7 days later then demonstrated a strongly positive functional HIPA test and confirmed the diagnosis of HIT. Under anticoagulation with argatroban the patient gradually improved and was finally weaned off the ECMO. In conclusion, this case highlights the critical importance of clinical judgement, exploiting the 4 T score, given that Covid-19 patients may present a different pattern of routine laboratory test results in HIT diagnostics. The possibility of a false negative HIPA test has to be considered, particularly in early phases of presentation. In cases of a discrepancy with high clinical probability of HIT and/or high titre anti-PF4/heparin antibodies despite a negative HIPA test, a reevaluation within 3 to 5 days after the initial test should be considered in order to avoid precipitant reestablishment of unfractionated heparin, with potentially fatal consequences. BioMed Central 2022-09-26 /pmc/articles/PMC9510722/ /pubmed/36163073 http://dx.doi.org/10.1186/s12959-022-00411-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Draxler, Dominik F. Brodard, Justine Zante, Björn Jakob, Stephan M. Wiegand, Jan Kremer Hovinga, Johanna A. Angelillo-Scherrer, Anne Rovo, Alicia The potential impact of Covid-19 on the capacity of routine laboratory tests to detect heparin-induced thrombocytopenia |
title | The potential impact of Covid-19 on the capacity of routine laboratory tests to detect heparin-induced thrombocytopenia |
title_full | The potential impact of Covid-19 on the capacity of routine laboratory tests to detect heparin-induced thrombocytopenia |
title_fullStr | The potential impact of Covid-19 on the capacity of routine laboratory tests to detect heparin-induced thrombocytopenia |
title_full_unstemmed | The potential impact of Covid-19 on the capacity of routine laboratory tests to detect heparin-induced thrombocytopenia |
title_short | The potential impact of Covid-19 on the capacity of routine laboratory tests to detect heparin-induced thrombocytopenia |
title_sort | potential impact of covid-19 on the capacity of routine laboratory tests to detect heparin-induced thrombocytopenia |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510722/ https://www.ncbi.nlm.nih.gov/pubmed/36163073 http://dx.doi.org/10.1186/s12959-022-00411-0 |
work_keys_str_mv | AT draxlerdominikf thepotentialimpactofcovid19onthecapacityofroutinelaboratoryteststodetectheparininducedthrombocytopenia AT brodardjustine thepotentialimpactofcovid19onthecapacityofroutinelaboratoryteststodetectheparininducedthrombocytopenia AT zantebjorn thepotentialimpactofcovid19onthecapacityofroutinelaboratoryteststodetectheparininducedthrombocytopenia AT jakobstephanm thepotentialimpactofcovid19onthecapacityofroutinelaboratoryteststodetectheparininducedthrombocytopenia AT wiegandjan thepotentialimpactofcovid19onthecapacityofroutinelaboratoryteststodetectheparininducedthrombocytopenia AT kremerhovingajohannaa thepotentialimpactofcovid19onthecapacityofroutinelaboratoryteststodetectheparininducedthrombocytopenia AT angelilloscherreranne thepotentialimpactofcovid19onthecapacityofroutinelaboratoryteststodetectheparininducedthrombocytopenia AT rovoalicia thepotentialimpactofcovid19onthecapacityofroutinelaboratoryteststodetectheparininducedthrombocytopenia AT draxlerdominikf potentialimpactofcovid19onthecapacityofroutinelaboratoryteststodetectheparininducedthrombocytopenia AT brodardjustine potentialimpactofcovid19onthecapacityofroutinelaboratoryteststodetectheparininducedthrombocytopenia AT zantebjorn potentialimpactofcovid19onthecapacityofroutinelaboratoryteststodetectheparininducedthrombocytopenia AT jakobstephanm potentialimpactofcovid19onthecapacityofroutinelaboratoryteststodetectheparininducedthrombocytopenia AT wiegandjan potentialimpactofcovid19onthecapacityofroutinelaboratoryteststodetectheparininducedthrombocytopenia AT kremerhovingajohannaa potentialimpactofcovid19onthecapacityofroutinelaboratoryteststodetectheparininducedthrombocytopenia AT angelilloscherreranne potentialimpactofcovid19onthecapacityofroutinelaboratoryteststodetectheparininducedthrombocytopenia AT rovoalicia potentialimpactofcovid19onthecapacityofroutinelaboratoryteststodetectheparininducedthrombocytopenia |